Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
Research ArticleOriginal Research

Contraceptive Methods and Informed Consent among Women Receiving Medications with Potential for Adverse Fetal Effects: A Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) Region Study

Rex W. Force, Gina A. Keppel, Janelle Guirguis-Blake, Debra A. Gould, Chris Vincent, Kavitha Chunchu, Robert M. Monger, John T. Holmes, Jacintha Cauffield and Laura-Mae Baldwin
The Journal of the American Board of Family Medicine September 2012, 25 (5) 661-668; DOI: https://doi.org/10.3122/jabfm.2012.05.120056
Rex W. Force
From the Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello (RWF, JTH); the Department of Family Medicine, University of Washington, Seattle (GAK, L-MB); the Tacoma Family Medicine Residency Program, Tacoma, WA (JG-B); the Central Washington Family Medicine Residency Program, Yakima, WA (DAG); the Swedish Family Medicine Residency–First Hill, Seattle, WA (CV); The Everett Clinic, Everett, WA (KC); the University of Wyoming Family Medicine Residency Program at Cheyenne, Cheyenne, WY (RMM); the Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL (JC).
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gina A. Keppel
From the Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello (RWF, JTH); the Department of Family Medicine, University of Washington, Seattle (GAK, L-MB); the Tacoma Family Medicine Residency Program, Tacoma, WA (JG-B); the Central Washington Family Medicine Residency Program, Yakima, WA (DAG); the Swedish Family Medicine Residency–First Hill, Seattle, WA (CV); The Everett Clinic, Everett, WA (KC); the University of Wyoming Family Medicine Residency Program at Cheyenne, Cheyenne, WY (RMM); the Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL (JC).
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janelle Guirguis-Blake
From the Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello (RWF, JTH); the Department of Family Medicine, University of Washington, Seattle (GAK, L-MB); the Tacoma Family Medicine Residency Program, Tacoma, WA (JG-B); the Central Washington Family Medicine Residency Program, Yakima, WA (DAG); the Swedish Family Medicine Residency–First Hill, Seattle, WA (CV); The Everett Clinic, Everett, WA (KC); the University of Wyoming Family Medicine Residency Program at Cheyenne, Cheyenne, WY (RMM); the Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL (JC).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debra A. Gould
From the Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello (RWF, JTH); the Department of Family Medicine, University of Washington, Seattle (GAK, L-MB); the Tacoma Family Medicine Residency Program, Tacoma, WA (JG-B); the Central Washington Family Medicine Residency Program, Yakima, WA (DAG); the Swedish Family Medicine Residency–First Hill, Seattle, WA (CV); The Everett Clinic, Everett, WA (KC); the University of Wyoming Family Medicine Residency Program at Cheyenne, Cheyenne, WY (RMM); the Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL (JC).
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Vincent
From the Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello (RWF, JTH); the Department of Family Medicine, University of Washington, Seattle (GAK, L-MB); the Tacoma Family Medicine Residency Program, Tacoma, WA (JG-B); the Central Washington Family Medicine Residency Program, Yakima, WA (DAG); the Swedish Family Medicine Residency–First Hill, Seattle, WA (CV); The Everett Clinic, Everett, WA (KC); the University of Wyoming Family Medicine Residency Program at Cheyenne, Cheyenne, WY (RMM); the Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL (JC).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kavitha Chunchu
From the Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello (RWF, JTH); the Department of Family Medicine, University of Washington, Seattle (GAK, L-MB); the Tacoma Family Medicine Residency Program, Tacoma, WA (JG-B); the Central Washington Family Medicine Residency Program, Yakima, WA (DAG); the Swedish Family Medicine Residency–First Hill, Seattle, WA (CV); The Everett Clinic, Everett, WA (KC); the University of Wyoming Family Medicine Residency Program at Cheyenne, Cheyenne, WY (RMM); the Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL (JC).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert M. Monger
From the Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello (RWF, JTH); the Department of Family Medicine, University of Washington, Seattle (GAK, L-MB); the Tacoma Family Medicine Residency Program, Tacoma, WA (JG-B); the Central Washington Family Medicine Residency Program, Yakima, WA (DAG); the Swedish Family Medicine Residency–First Hill, Seattle, WA (CV); The Everett Clinic, Everett, WA (KC); the University of Wyoming Family Medicine Residency Program at Cheyenne, Cheyenne, WY (RMM); the Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL (JC).
MD, FACP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John T. Holmes
From the Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello (RWF, JTH); the Department of Family Medicine, University of Washington, Seattle (GAK, L-MB); the Tacoma Family Medicine Residency Program, Tacoma, WA (JG-B); the Central Washington Family Medicine Residency Program, Yakima, WA (DAG); the Swedish Family Medicine Residency–First Hill, Seattle, WA (CV); The Everett Clinic, Everett, WA (KC); the University of Wyoming Family Medicine Residency Program at Cheyenne, Cheyenne, WY (RMM); the Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL (JC).
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacintha Cauffield
From the Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello (RWF, JTH); the Department of Family Medicine, University of Washington, Seattle (GAK, L-MB); the Tacoma Family Medicine Residency Program, Tacoma, WA (JG-B); the Central Washington Family Medicine Residency Program, Yakima, WA (DAG); the Swedish Family Medicine Residency–First Hill, Seattle, WA (CV); The Everett Clinic, Everett, WA (KC); the University of Wyoming Family Medicine Residency Program at Cheyenne, Cheyenne, WY (RMM); the Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL (JC).
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura-Mae Baldwin
From the Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello (RWF, JTH); the Department of Family Medicine, University of Washington, Seattle (GAK, L-MB); the Tacoma Family Medicine Residency Program, Tacoma, WA (JG-B); the Central Washington Family Medicine Residency Program, Yakima, WA (DAG); the Swedish Family Medicine Residency–First Hill, Seattle, WA (CV); The Everett Clinic, Everett, WA (KC); the University of Wyoming Family Medicine Residency Program at Cheyenne, Cheyenne, WY (RMM); the Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL (JC).
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

References

  1. 1.↵
    1. Egan BM,
    2. Zhao Y,
    3. Axon RN
    . US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 2010;303:2043–50.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Hyre AD,
    2. Muntner P,
    3. Menke A,
    4. Raggi P,
    5. He J
    . Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol 2007;17:548–55.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Mann D,
    2. Reynolds K,
    3. Smith D,
    4. Muntner P
    . Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008;42:1208–15.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Centers for Disease Control and Prevention. Diabetes data & trends. Number (in millions) of civilian, non-institutionalized persons with diagnosed diabetes, United States, 1980–2009. Available from: http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm. Accessed August 18, 2011.
  5. 5.↵
    1. Chobanian AV,
    2. Bakris GL,
    3. Black HR,
    4. et al
    . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Martin U,
    2. Foreman MA,
    3. Travis JC,
    4. Casson D,
    5. Coleman JJ
    . Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther 2008;33:507–11.
    OpenUrlPubMed
  7. 7.↵
    Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol–United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep 2011;60:109–14.
    OpenUrlPubMed
  8. 8.↵
    Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of hypertension–United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep 2011;60:103–8.
    OpenUrlPubMed
  9. 9.↵
    1. Cooper WO,
    2. Hernandez-Diaz S,
    3. Arbogast PG,
    4. et al
    . Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443–51.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Quan A
    . Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006;82:23–8.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Edison RJ,
    2. Muenke M
    . Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 2004;131:287–98.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Edison RJ,
    2. Muenke M
    . Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 2004;350:1579–82.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Kazmin A,
    2. Garcia-Bournissen F,
    3. Koren G
    . Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 2007;29:906–8.
    OpenUrlPubMed
  14. 14.↵
    1. Bowen ME,
    2. Ray WA,
    3. Arbogast PG,
    4. Ding H,
    5. Cooper WO
    . Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy. Am J Obstet Gynecol 2008;198:291.e1–5.
    OpenUrlPubMed
  15. 15.↵
    1. Lee C,
    2. Force RW,
    3. Pugmire BA,
    4. Owens CT
    . Use of ACE-inhibitors, angiotensin II receptor blockers, and statins in women of childbearing age. Pharmacotherapy 2008;28:72e.
    OpenUrl
  16. 16.↵
    1. Schwarz EB,
    2. Longo LS,
    3. Zhao X,
    4. Stone RA,
    5. Cunningham F,
    6. Good CB
    . Provision of potentially teratogenic medications to female veterans of childbearing age. Med Care 2010;48:834–42.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Schwarz EB,
    2. Postlethwaite DA,
    3. Hung YY,
    4. Armstrong MA
    . Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann Intern Med 2007;147:370–6.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Eisenberg DL,
    2. Stika C,
    3. Desai A,
    4. Baker D,
    5. Yost KJ
    . Providing contraception for women taking potentially teratogenic medications: a survey of internal medicine physicians' knowledge, attitudes and barriers. J Gen Intern Med 2010;25:291–7.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Morrical-Kline KA,
    2. Walton AM,
    3. Guildenbecher TM
    . Teratogen use in women of childbearing potential: an intervention study. J Am Board Fam Med 2011;24:262–71.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Schwarz EB,
    2. Maselli J,
    3. Norton M,
    4. Gonzales R
    . Prescription of teratogenic medications in United States ambulatory practices. Am J Med 2005;118:1240–9.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Schwarz EB,
    2. Santucci A,
    3. Borrero S,
    4. Akers AY,
    5. Nikolajski C,
    6. Gold MA
    . Perspectives of primary care clinicians on teratogenic risk counseling. Birth Defects Res A Clin Mol Teratol 2009;85:858–63.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Santucci AK,
    2. Gold MA,
    3. Akers AY,
    4. Borrero S,
    5. Schwarz EB
    . Women's perspectives on counseling about risks for medication-induced birth defects. Birth Defects Res A Clin Mol Teratol 2009;88:64–9.
    OpenUrl
  23. 23.↵
    1. Lohr PA,
    2. Schwarz EB,
    3. Gladstein JE,
    4. Nelson AL
    . Provision of contraceptive counseling by internal medicine residents. J Womens Health (Larchmt) 2009;18:127–31.
    OpenUrlPubMed
  24. 24.↵
    1. Weisman CS,
    2. Maccannon DS,
    3. Henderson JT,
    4. Shortridge E,
    5. Orso CL
    . Contraceptive counseling in managed care: preventing unintended pregnancy in adults. Womens Health Issues 2002;12:79–95.
    OpenUrlPubMed
  25. 25.↵
    1. Steinkellner A,
    2. Chen W,
    3. Denison SE
    . Adherence to oral contraception in women on Category X medications. Am J Med 2010;123:929–34 e1.
    OpenUrlPubMed
  26. 26.↵
    1. Darden PM,
    2. Ector W,
    3. Moran C,
    4. Quattlebaum TG
    . Comparison of continuity in a resident versus private practice. Pediatrics 2001;108:1263–8.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Gallagher TH,
    2. Waterman AD,
    3. Ebers AG,
    4. Fraser VJ,
    5. Levinson W
    . Patients' and physicians' attitudes regarding the disclosure of medical errors. JAMA 2003;289:1001–7.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Mosher WD,
    2. Jones J
    . Use of contraception in the United States: 1982–2008. Vital Health Stat 23. 2010;(29):1–44.
  29. 29.↵
    1. Schwarz EB,
    2. Postlethwaite D,
    3. Hung YY,
    4. Lantzman E,
    5. Armstrong MA,
    6. Horberg MA
    . Provision of contraceptive services to women with diabetes mellitus. J Gen Intern Med 2012;27:196–201.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 25 (5)
The Journal of the American Board of Family Medicine
Vol. 25, Issue 5
September-October 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Contraceptive Methods and Informed Consent among Women Receiving Medications with Potential for Adverse Fetal Effects: A Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) Region Study
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Contraceptive Methods and Informed Consent among Women Receiving Medications with Potential for Adverse Fetal Effects: A Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) Region Study
Rex W. Force, Gina A. Keppel, Janelle Guirguis-Blake, Debra A. Gould, Chris Vincent, Kavitha Chunchu, Robert M. Monger, John T. Holmes, Jacintha Cauffield, Laura-Mae Baldwin
The Journal of the American Board of Family Medicine Sep 2012, 25 (5) 661-668; DOI: 10.3122/jabfm.2012.05.120056

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Contraceptive Methods and Informed Consent among Women Receiving Medications with Potential for Adverse Fetal Effects: A Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) Region Study
Rex W. Force, Gina A. Keppel, Janelle Guirguis-Blake, Debra A. Gould, Chris Vincent, Kavitha Chunchu, Robert M. Monger, John T. Holmes, Jacintha Cauffield, Laura-Mae Baldwin
The Journal of the American Board of Family Medicine Sep 2012, 25 (5) 661-668; DOI: 10.3122/jabfm.2012.05.120056
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Notes
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Pregnancy protection and pregnancies in women prescribed ACE inhibitors or ARBs: a cross-sectional study in primary care
  • Prostate Cancer Decision-Making, Health Services, and the Family Physician Workforce
  • Primary Care Research Conducted in Networks: Getting Down to Business
  • Google Scholar

More in this TOC Section

  • A Pilot Comparison of Clinical Data Collection Methods Using Paper, Electronic Health Record Prompt, and a Smartphone Application
  • Associations Between Modifiable Preconception Care Indicators and Pregnancy Outcomes
  • Perceptions and Preferences for Defining Biosimilar Products in Prescription Drug Promotion
Show more Original Research

Similar Articles

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire